1. What the law is
Two psychedelic laws passed in Georgia in 2026 and neither of them opens a door. HB 382 excepts FDA-approved crystalline polymorph psilocybin from Schedule I by deferring to federal scheduling, so it does nothing until the FDA acts. HB 717 directs the Georgia Composite Medical Board to regulate clinics that administer psychedelic-assisted therapies. Psilocybin stays in Schedule I and possession stays prohibited. The veterans pilot bill, HB 1296, died at adjournment.
Manufacture, distribution and possession all carry criminal penalties in Georgia, where psilocybin sits in Schedule I of the Georgia Controlled Substances Act at O.C.G.A. Section 16-13-25. The 2026 session produced two psychedelics laws, HB 382 and HB 717, and left that listing intact. One waits on a federal decision that has not come; the other regulates how clinics operate. Neither opens a legal route to psilocybin today.
Psilocybin is currently illegal in Georgia and there is no lawful route to possess or use it. Governor Brian Kemp signed HB 382 in 2026, a trigger law that revises the state's Schedule I to except crystalline polymorph psilocybin only if and when the substance receives federal FDA approval and corresponding DEA rescheduling; because no FDA-approved psilocybin product exists as of June 2026, HB 382 confers no present legal access. Kemp also signed HB 717 on May 12, 2026, enacted as Act 634, which amends the Medical Practice Act to have the Georgia Composite Medical Board regulate clinics administering psychedelic-assisted treatment and therapy, with rules due by December 31, 2026 and clinic compliance required by July 1, 2027; this regulatory framework governs the conduct of clinics for already-permitted therapies and does not itself legalize psilocybin. Two veterans-focused measures, HB 1296 (a breakthrough-treatments pilot for veterans and first responders) and HB 1297 (psychedelic-assisted treatment upon FDA approval), did not pass before the 2025-2026 legislative session adjourned sine die.
2. Trials in Georgia
Interventional psilocybin trials with at least one site in Georgia, as their sponsors filed them with ClinicalTrials.gov, EU CTIS and ISRCTN. Each row links to the registry record, which sets out who may take part.
Recruiting or opening counts trials recruiting now, not yet recruiting, or enrolling by invitation. Closed counts trials terminated, suspended, withdrawn or left unverified by their sponsors.
| Registry ID | Trial | Phase | Sponsor | Status | Start date |
|---|---|---|---|---|---|
| NCT07332143 | Psilocybin-Assisted Therapy (opens in new tab)Recruiting at Emory University Hospital, Atlanta | Phase Phase 2 | Sponsor Emory University | Status Recruiting | Start date |
| NCT07516405 | Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (opens in new tab)Recruiting at Emory University Brain Health Center, Atlanta | Phase Phase 1 | Sponsor University of Colorado, Denver | Status Recruiting | Start date |
| NCT06793397 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Recruiting at Psych Atlanta, Marietta | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Recruiting | Start date |
| NCT06605105 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (opens in new tab)Sites in Atlanta and Savannah | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Enrolling by invitation | Start date |
| NCT06564818 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Sites in Atlanta, Decatur, Savannah | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Active, not recruiting | Start date |
| NCT06308653 | Psilocybin for Major Depressive Disorder (MDD) (opens in new tab)Sites in Atlanta and Decatur | Phase Phase 3 | Sponsor Usona Institute | Status Active, not recruiting | Start date |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (opens in new tab)Sites in Atlanta and Decatur | Phase Phase 3 | Sponsor COMPASS Pathways | Status Active, not recruiting | Start date |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (opens in new tab)Two sites in Atlanta | Phase Phase 3 | Sponsor COMPASS Pathways | Status Completed | Start date |
| NCT05506982 | Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (opens in new tab)Two sites in Atlanta | Phase Phase 1 | Sponsor Emory University | Status Completed | Start date |
| NCT05385783 | A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder (opens in new tab)Sites in Atlanta and Decatur | Phase Phase 1/2 | Sponsor Cybin IRL Limited | Status Completed | Start date |
| NCT04519957 | Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) (opens in new tab)Site at Mood and Anxiety Disorders Program Emory University School of Medicine, Atlanta | Phase Not stated | Sponsor COMPASS Pathways | Status Completed | Start date |
| NCT03866174 | A Study of Psilocybin for Major Depressive Disorder (MDD) (opens in new tab)Site at Emory University, Atlanta | Phase Phase 2 | Sponsor Usona Institute | Status Completed | Start date |
ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.
1 more trial on file for Georgia.
The register lists all 13 and filters them by condition, status and phase.
3. History
The legal events behind this entry, dated and oldest first. Our own reviews and corrections are listed under Changes to this record.
Governor Brian Kemp signs HB 382, revising Schedule I to except future FDA-approved crystalline polymorph psilocybin by deferring to federal DEA scheduling; no FDA-approved psilocybin product exists, so the exception is not yet operative.
HB 1296 (breakthrough-treatments pilot for veterans and first responders) and HB 1297 (psychedelic-assisted treatment upon FDA approval) fail to pass before the 2025-2026 session adjourns sine die.
Governor Brian Kemp signs HB 717, amending the Medical Practice Act to regulate clinics administering psychedelic-assisted treatment and therapy; implementing rules are due December 31, 2026 and clinic compliance is required by July 1, 2027.
4. Proposed laws
No proposed law is on file in Georgia that would change this entry, as of the 01 Aug 2026 review.
5. Common questions
Is psilocybin legal in Georgia?
No. Psilocybin is a Schedule I controlled substance under the Georgia Controlled Substances Act (O.C.G.A. § 16-13-25), and its manufacture, distribution, and possession are illegal and subject to criminal penalties.
Did HB 382 legalize psilocybin in Georgia?
No. HB 382 is a trigger law that excepts a future FDA-approved crystalline polymorph form of psilocybin from Schedule I only by deferring to federal DEA scheduling. Because no FDA-approved psilocybin product exists as of June 2026, the exception is not yet operative and psilocybin remains illegal in Georgia.
What does HB 717 do?
HB 717, signed May 25, 2026, amends the Medical Practice Act to have the Georgia Composite Medical Board regulate clinics administering psychedelic-assisted treatment and therapy, with rules due by December 31, 2026 and clinic compliance required by July 1, 2027. It establishes a regulatory framework for clinic conduct and does not legalize psilocybin.
Is there any legal psilocybin program for veterans in Georgia?
No. HB 1296, a proposed breakthrough-treatments pilot for veterans and first responders, and HB 1297, addressing psychedelic-assisted treatment upon FDA approval, did not pass before the 2025-2026 legislative session adjourned, so no such program exists in Georgia.
Are magic mushrooms ("shrooms") legal in Georgia?
"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin, and this entry states the law on psilocybin itself, which some laws treat separately from the fungus. Psilocybin is illegal in Georgia.
Read the law
HB 382 / Act 476 (signed May 11, 2026): revises Schedule I to except FDA-approved crystalline polymorph psilocybin, deferring to federal DEA scheduling; operative only upon FDA approval, DEA scheduling, and federal CSA listing (trigger law; no current access). HB 717 / Act 634 (signed May 12, 2026, effective July 1, 2026): Medical Practice Act regulation of clinics administering psychedelic-assisted treatment (Composite Medical Board rules due December 31, 2026; clinic licensure required on and after July 1, 2027).1
Sources
This entry's status is checked against the primary sources below, and the methodology explains how each entry is graded for confidence.
- 1.gov.georgia.gov (opens in new tab) · gov.georgia.gov
- 2.healthesystems.com (opens in new tab) · healthesystems.com
This entry is for information only and is not legal or medical advice. Laws change, and enforcement can differ from the letter of the law, so check the current position against the primary sources above before relying on it.
Changes to this record
2 changes on file, the latest on . Show allHide
Every change we have made to this record, dated, corrections included. Nothing changes silently.
Georgia's veterans psychedelic pilot bill died at adjournment, and a bill number long recorded beside it turned out to be a court-fee act. Nothing is pending; the state's two 2026 psychedelic laws stand.
Georgia's two 2026 psychedelic laws do not let anyone use psilocybin: one waits on federal approval, the other regulates clinics. The entry now reads illegal.
Psilocybin Media Group. "Georgia: psilocybin legal status." The Psilocybin Record, accession US-GA-001, version of 23 Aug 2026. https://psilocybinlegalization.com/record/georgia